Alpha Omega Trial: Study of Omega-3 Fatty Acids and Coronary Mortality
Alpha Omega Trial: A Randomised, Placebo Controlled, Double Blind Intervention Study of the Effect of Low Doses of Omega-3 Fatty Acids on Cardiovascular Diseases in Patients With a History of Myocardial Infarction
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
This NA trial investigates Cardiovascular Diseases and is currently completed. National Heart, Lung, and Blood Institute (NHLBI) leads this study, which shows 6 recorded versions since 2002 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed NA
First recorded
Apr 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Heart, Lung, and Blood Institute (NHLBI)
- Netherlands Heart Foundation
- Unilever R&D
- Wageningen University
For direct contact, visit the study record on ClinicalTrials.gov .